Clinical trials: Glial Tumor
Glioblastoma, Gliosarcoma
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Primary objective: To estimate 6-month progression free survival probability of pts w recurrent malignant gliomas treated w erlotinib + bevacizumab.
- Trial name
- NCT00671970
- Testing
- Bevacizumab and Erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Glioma, Malignant, Metastases to Brain
Concurrent Fluorescence and Sonographically Guided Eradication of High-grade Gliomas and Metastases
The objective of the study is to determine whether the combined use of intraoperative fluorescence with 5-aminolevulinic acid (5-ALA) and sonography can achieve a higher rate of gross total resection in hemispheric high-grade…
- Trial name
- CONFLUENCE (NCT05474573)
- Testing
- Combined ultrasound and fluorescence-guided brain tumor resection, Fluorescence-guided brain tumor resection
- Where
- Russia
- Volunteers
- 52 people
- Sponsor
- Sklifosovsky Institute of Emergency Care
Brain and Central Nervous System Tumors
Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003375
- Testing
- lomustine, procarbazine hydrochloride, vincristine sulfate
- Volunteers
- 370 people
- Sponsor
- Radiation Therapy Oncology Group
High Grade Gliomas, Glioblastoma
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
Better treatments are needed for high-grade gliomas (HGG), and new ways of treating this disease should be tested. The investigators want to see if giving medicine before radiation works well.
- Conditions
- High Grade Gliomas, Glioblastoma, Astrocytoma, Oligodendroglioma
- Trial name
- PRC (NCT07439172)
- Testing
- Pre-radiation temozolomide.
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cooper Health System
Pediatric Brain Stem Glioma
Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children
This Trial offers a reduction in patient burden, which is especially preferable in children with a poor compliance and poor performance status.
- Trial name
- NCT01878266
- Testing
- Hypofractionated Arm (1), Hypofractionated Arm (2), Conventional Arm (3)
- Where
- Egypt
- Volunteers
- 119 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Glioma
Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma
Gliomas are the most common type of primary brain tumors, with surgery followed by radiotherapy and chemotherapy as the main treatment modalities.
- Trial name
- NCT06330337
- Testing
- Temozolomide（TMZ） injection or oral administration, Albumin-Bound Paclitaxel(ABX) intravenous drip, Specific mode electroacupuncture stimulation(SMES) intervention
- Where
- China
- Volunteers
- 58 people
- Sponsor
- The Third Affiliated hospital of Zhejiang Chinese Medical University
Tumor, Brain, Meningioma of Brain
Sonography-guided Resection of Brain Mass Lesions
The study aims to perform a comparative analysis of preoperative CT/MRI and intraoperative ultrasound findings in patients with hemispheric brain tumors (meningiomas, gliomas, metastases), and to develop an intraoperative…
- Conditions
- Tumor, Brain, Meningioma of Brain, Glioma, Metastasis Brain
- Trial name
- SOMALI (NCT05484245)
- Testing
- Sonography
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Sklifosovsky Institute of Emergency Care
Recurrent Glioblastoma or Other Glioma Subtypes
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating…
- Trial name
- NCT01975701
- Testing
- BGJ398
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Glioblastoma Multiforme
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma.
- Trial name
- NCT00071539
- Testing
- TP-38, TP38
- Volunteers
- 56 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Glioblastoma Multiforme
Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
The purpose of this study is to determine whether a combination of Sunitinib, Temozolomide and Radiation Therapy would be effective in the treatment of newly diagnosed Glioblastoma patients harboring tumors with unmethylated MGMT…
- Trial name
- NCT02928575
- Testing
- Sunitinib, Temozolomide, Radiation Therapy
- Where
- 2 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Bassam Abdulkarim
Glioma, Glioblastoma
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of…
- Conditions
- Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma
- Trial name
- NCT07541781
- Testing
- Sitagliptin, Bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Kailin Yang, MD, PhD
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
The standard of care for children with DIPG includes focal radiotherapy (RT) but outcomes have remained dismal despite this treatment.
- Trial name
- BRAVO (NCT03396575)
- Testing
- TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Florida
Glioblastoma Multiforme
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three different dose levels. Phase 2a of the study, will further evaluate the safety, tolerability, and in addition efficacy of AQ4N treatment…
- Trial name
- NCT00394628
- Testing
- AQ4N, Temozolomide, Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novacea
Glioblastoma, Brain Metastases
PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404 PET/CT in humans with brain metastases and GBMs.
- Trial name
- NCT01516905
- Testing
- NM404
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Glioblastoma Multiforme
Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]
Glioblastoma multiforme (GBM WHO IV) is the most common and aggressive primary brain tumor in adults, carrying a poor prognosis with a median survival of 12-16 months.
- Trial name
- TYR-GLIO (NCT06466031)
- Testing
- MRI & PET fusion, MRI+T1C
- Where
- Poland
- Volunteers
- 189 people
- Sponsor
- Copernicus Memorial Hospital
Malignant Glioma
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
The purpose of this study is to see if the addition of the investigation drug called pembrolizumab (Keytruda®) to radiation therapy and bevacizumab (Avastin®) is safe and can help with controlling the growth of tumors, in…
- Trial name
- NCT02313272
- Testing
- Hypofractionated Stereotactic Irradiation (HFSRT), Pembrolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Glioblastoma Multiforme
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy.
- Trial name
- RESTORE (NCT03862430)
- Testing
- NanO2TM
- Where
- 12 sites in United States
- Volunteers
- 87 people
- Sponsor
- NuvOx LLC
Recurrent Glioblastoma, Gliosarcoma
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
This is a study to determine the efficacy, safety and clinical benefit (how well the drugs works), of the pharmaceutical compositions in Nasal Spray NST-4G for the treatment of brain tumors( Recurrent Glioblastoma…
- Conditions
- Recurrent Glioblastoma, Gliosarcoma, Anaplastic Gliomas
- Trial name
- NCT03275558
- Testing
- Axitinib 1 MG, Sunitinib 5 MG, Pazopanib 5 MG
- Where
- 2 sites in Hong Kong, Singapore
- Sponsor
- Center Trials & Treatment
Glioblastoma
POSitron Emission Imaging Using 18F-FDOPA in Neurooncology
18F-FDOPA PET is expensive. It is mandatory therefore to assess its impact on the management of patients with high-grade gliomas in order to provide medico-economic justification for its use.
- Trial name
- POSEIDON (NCT02631655)
- Testing
- impact of device 18F-FDOPA PET on treatment decisions
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.